Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Research Progress of Anti-Hepatic Fibrosis Drug Treatment

SHI Xiangtian;OUYANG Xiaohui;SU Xiulan;Graduate School,Inner Mongolia University of Science and Technology Baotou Medical College;Clinical Medical Research Center,the Affiliated Hospital of Inner Mongolia Medical University;Department of Hepatobiliary,Pancreatic and Splenic Surgery,Inner Mongolia People's Hospital;  
The continuous action of various injury factors causes apoptosis of liver cells leading to an inflammatory response. Hepatic stellate cells( HSCs) are activated and transformed into myofibroblasts,causing excessive deposition of extracellular matrix( ECM),leading to local hepatic lobular scar formation,causing changes in liver parenchyma and vascular structure,and nodular regeneration,which are formed by hepatic fibrosis. The main feature,if not intervened,will progress to cirrhosis. In addition to hepatocyte injury factors,the reduction or recovery of activated HSCs to a resting state,resulting in excessive deposition of ECM degradation,etc.,is a key point for drug treatment of liver fibrosis. Drugs can inhibit the replication of hepatitis virus,regulate lipid metabolism; reduce the activation of HSCs,increase the anti-inflammatory and anti-oxidation levels; regulate the transition of ECM transformation to the direction of degradation,and intervene the process of liver fibrosis caused by different factors. At present,anti-hepatic fibrosis treatment is still based on the single drug targeted at the cause of hepatic fibrosis. In the future,according to the principle of drug action,multiple drugs can be combined to improve the efficacy and reduce the drug dosage.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved